New drug combo targets genetic flaw in aggressive blood cancers
NCT ID NCT06597734
Summary
This study is testing whether adding the drug olutasidenib to standard chemotherapy can better control advanced blood cancers in patients who have a specific genetic mutation (IDH1). It aims to see if this combination is safe and effective at reducing the disease. The trial is for adults with certain high-risk forms of myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.